BINDING OF ENDOTHELIN TO PLASMA-PROTEINS AND TISSUE RECEPTORS - EFFECTS ON ENDOTHELIN DETERMINATION, VASOACTIVITY, AND TISSUE KINETICS

被引:14
作者
BRUNNER, F
STESSEL, H
WATZINGER, N
LOFFLER, BM
OPIE, LH
机构
[1] GRAZ UNIV,MED UNIV KLIN,A-8036 GRAZ,AUSTRIA
[2] F HOFFMANN LA ROCHE & CO LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND
[3] UNIV CAPE TOWN,SCH MED,ISCHAEM HEART DIS RES UNIT,CAPE TOWN 7925,SOUTH AFRICA
基金
英国医学研究理事会;
关键词
PLASMA PROTEIN BINDING; ENDOTHELIN-1; BIG ENDOTHELIN-1; VASOACTIVITY; TISSUE KINETICS; CONGESTIVE HEART FAILURE; MYOCARDIAL INFARCTION;
D O I
10.1016/0014-5793(95)01017-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vitro binding of (3-[I-125]Tyr)-endothelin-1 ([I-125]ET-1) and (3-[I-125]Tyr)-big ET-1(1-38) ([I-125]big ET-1) to plasma proteins of healthy humans, cardiac patients and normotensive and hypertensive rats was investigated by equilibrium dialysis. Binding of both tracers was similar in plasma from healthy humans, patients with congestive heart failure, and following myocardial infarction (similar to 60%), and marginally higher in rat plasmas (similar to 70%). Binding of [I-125]ET-1 to human plasma could be explained by binding to human serum albumin. Endogenous plasma ET-1 levels were similar to 9 pg/ml in healthy humans, and similar to 12-16 pg/ml in cardiac patients; big ET-1 concentrations were approximately two- to threefold higher. ET-1 bound to plasma protein was partly lost in column extraction. In rat isolated perfused hearts, the coronary dilator and constrictor potency of exogenous free and albumin-bound ET-1 was similar, whereas the kinetics of endogenous ET-1 was impeded by tight binding to ET receptors. The data indicate that binding of ET-1 to plasma proteins is without effect on peptide vasoactivity, but binding to tissue receptors greatly impedes its tissue kinetics.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 23 条
[1]   EFFECT OF INTRACELLULAR CA2+ CONCENTRATION ON ENDOTHELIN-1 SECRETION [J].
BRUNNER, F ;
STESSEL, H ;
SIMECEK, S ;
GRAIER, W ;
KUKOVETZ, WR .
FEBS LETTERS, 1994, 350 (01) :33-36
[2]  
BRUNNER F, 1995, IN PRESS
[3]  
BRUNNER F, 1984, J PHARM PHARMACOL, V37, P305
[4]   NOVEL RECEPTOR ANTAGONISTS WELCOME A NEW ERA IN ENDOTHELIN BIOLOGY [J].
DOUGLAS, SA ;
MEEK, TD ;
OHLSTEIN, EH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1994, 15 (09) :313-316
[5]   WHY ARE CIRCULATING CONCENTRATIONS OF ENDOTHELIN-1 SO LOW [J].
FRELIN, C ;
GUEDIN, D .
CARDIOVASCULAR RESEARCH, 1994, 28 (11) :1613-1622
[6]   IMPORTANCE OF PROTEIN-BINDING FOR THE INTERPRETATION OF SERUM OR PLASMA DRUG CONCENTRATIONS [J].
GREENBLATT, DJ ;
SELLERS, EM ;
KOCHWESER, J .
JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (5-6) :259-263
[7]  
HULSE M, 1981, J PHARMACOL EXP THER, V218, P416
[8]   PLASMA-IMMUNOREACTIVE ENDOTHELIN IN ESSENTIAL-HYPERTENSION [J].
KOHNO, M ;
YASUNARI, K ;
MURAKAWA, KI ;
YOKOKAWA, K ;
HORIO, T ;
FUKUI, T ;
TAKEDA, T .
AMERICAN JOURNAL OF MEDICINE, 1990, 88 (06) :614-618
[9]   ENDOTHELINS - MYOCARDIAL ACTIONS OF A NEW CLASS OF CYTOKINES [J].
KRAMER, BK ;
NISHIDA, M ;
KELLY, RA ;
SMITH, TW .
CIRCULATION, 1992, 85 (01) :350-356
[10]   PROTEIN-BINDING AS A PRIMARY DETERMINANT OF THE CLINICAL PHARMACOKINETIC PROPERTIES OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].
LIN, JH ;
COCCHETTO, DM ;
DUGGAN, DE .
CLINICAL PHARMACOKINETICS, 1987, 12 (06) :402-432